Total Payments
$146,354
2024 Payments
$2,786
Companies
81
Transactions
1,422
Medicare Patients
4,320
Medicare Billing
$275,164
Payment Breakdown by Category
Research$71,006 (48.5%)
Other$35,505 (24.3%)
Food & Beverage$24,919 (17.0%)
Travel$7,492 (5.1%)
Consulting$7,155 (4.9%)
Education$277.18 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $71,006 | 9 | 48.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,505 | 43 | 24.3% |
| Food and Beverage | $24,919 | 1,324 | 17.0% |
| Travel and Lodging | $7,492 | 25 | 5.1% |
| Consulting Fee | $7,155 | 2 | 4.9% |
| Education | $277.18 | 19 | 0.2% |
Payments by Type
General
$75,348
1,413 transactions
Research
$71,006
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $46,485 | 3 | $0 (2023) |
| Indivior Inc. | $43,119 | 105 | $0 (2024) |
| Braeburn Pharmaceuticals, Inc. | $22,702 | 10 | $0 (2017) |
| Novo Nordisk Inc | $10,771 | 211 | $0 (2024) |
| Orexo US, Inc. | $4,427 | 11 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $2,506 | 119 | $0 (2024) |
| Lilly USA, LLC | $1,741 | 116 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,061 | 61 | $0 (2024) |
| Amgen Inc. | $1,055 | 59 | $0 (2024) |
| PFIZER INC. | $1,018 | 76 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,786 | 139 | Novo Nordisk Inc ($367.10) |
| 2023 | $14,649 | 146 | Eli Lilly and Company ($11,663) |
| 2022 | $37,706 | 177 | Eli Lilly and Company ($33,144) |
| 2021 | $7,108 | 185 | Orexo US, Inc. ($2,510) |
| 2020 | $2,567 | 175 | Novo Nordisk Inc ($355.43) |
| 2019 | $16,098 | 170 | Indivior Inc. ($9,764) |
| 2018 | $39,190 | 236 | Indivior Inc. ($32,201) |
| 2017 | $26,249 | 194 | Braeburn Pharmaceuticals, Inc. ($22,702) |
All Payment Transactions
1,422 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $33.77 | General |
| 12/11/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Opioid Use Disorder | ||||||
| 12/05/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: Central Nervous System | ||||||
| 12/03/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Endocrinology | ||||||
| 11/20/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Neurology | ||||||
| 11/18/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Neurology | ||||||
| 11/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Central Nervous System | ||||||
| 11/11/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Insomnia | ||||||
| 11/08/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $13.08 | General |
| Category: GI | ||||||
| 11/06/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: PSYCHIATRY | ||||||
| 11/04/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Inflammation | ||||||
| 10/31/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Neurology | ||||||
| 10/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: OUD | ||||||
| 10/16/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $34,822 | 2 |
| HS-14-499 | Braeburn Pharmaceuticals, Inc. | $18,037 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $11,663 | 1 |
| OXD01-001 | Orexo US, Inc. | $4,333 | 4 |
| HS-11-421 | Braeburn Pharmaceuticals, Inc. | $2,151 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 642 | 1,843 | $93,032 | $48,080 |
| 2022 | 15 | 783 | 2,099 | $104,594 | $55,605 |
| 2021 | 19 | 1,538 | 3,359 | $144,060 | $84,085 |
| 2020 | 29 | 1,357 | 2,993 | $179,020 | $87,394 |
Total Patients
4,320
Total Services
10,294
Medicare Billing
$275,164
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 132 | 301 | $45,150 | $23,078 | 51.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 73 | 73 | $10,877 | $8,884 | 81.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 152 | $14,136 | $8,716 | 61.7% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 99 | 213 | $8,520 | $2,631 | 30.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $3,710 | $1,591 | 42.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 52 | 162 | $5,600 | $1,545 | 27.6% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 57 | 57 | $2,850 | $972.42 | 34.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 13 | 14 | $896.00 | $296.52 | 33.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 27 | 34 | $166.00 | $115.94 | 69.8% |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | Office | 2023 | 20 | 50 | $100.00 | $72.22 | 72.2% |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | Office | 2023 | 14 | 19 | $76.00 | $56.52 | 74.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 34 | 566 | $566.00 | $50.56 | 8.9% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 15 | 88 | $85.00 | $36.23 | 42.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 16 | 100 | $300.00 | $35.10 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 163 | 363 | $54,450 | $28,229 | 51.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 97 | 97 | $14,453 | $12,181 | 84.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 80 | 132 | $12,276 | $7,663 | 62.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 108 | 170 | $6,800 | $2,123 | 31.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 68 | 193 | $6,755 | $1,946 | 28.8% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 97 | 97 | $4,850 | $1,683 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $3,180 | $1,269 | 39.9% |
| 92228 | Imaging of retina with remote review by physician | Office | 2022 | 13 | 13 | $286.00 | $120.64 | 42.2% |
| 81002 | Urinalysis, manual test | Office | 2022 | 25 | 27 | $108.00 | $92.52 | 85.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 41 | 744 | $744.00 | $64.29 | 8.6% |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | Office | 2022 | 18 | 44 | $88.00 | $63.51 | 72.2% |
About Dr. James Sullivan, MD
Dr. James Sullivan, MD is a Internal Medicine healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588613020.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Sullivan, MD has received a total of $146,354 in payments from pharmaceutical and medical device companies, with $2,786 received in 2024. These payments were reported across 1,422 transactions from 81 companies. The most common payment nature is "" ($71,006).
As a Medicare-enrolled provider, Sullivan has provided services to 4,320 Medicare beneficiaries, totaling 10,294 services with total Medicare billing of $275,164. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Birmingham, AL
- Active Since 05/10/2006
- Last Updated 07/20/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1588613020
Products in Payments
- SUBLOCADE (Drug) $34,190
- CAM2038q1w $20,188
- Victoza (Drug) $8,263
- SUBOXONE SUBLINGUAL FILM (Drug) $6,878
- CAM2038 $1,651
- FARXIGA (Drug) $1,369
- Ozempic (Drug) $1,125
- TRELEGY ELLIPTA (Drug) $847.03
- TRULICITY (Drug) $781.37
- Probuphine (Drug) $772.41
- Rybelsus (Drug) $698.65
- XARELTO (Drug) $664.56
- JARDIANCE (Drug) $604.74
- XIFAXAN (Drug) $596.95
- CAPLYTA (Drug) $552.52
- VRAYLAR (Drug) $552.12
- NURTEC ODT (Drug) $530.28
- Senza Spinal Cord Stimulation System (Device) $505.12
- FASENRA (Biological) $442.00
- EMGALITY (Drug) $386.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Birmingham
Ryan Weldon, M.d, M.D
Internal Medicine — Payments: $380,099
Internal Medicine $380,099
Rudolph Navari, M.d, M.D
Internal Medicine — Payments: $335,135
Internal Medicine $335,135
Dr. Robert Lewis, M.d, M.D
Internal Medicine — Payments: $176,028
Internal Medicine $176,028
Jose Vargas, M.d, M.D
Internal Medicine — Payments: $140,921
Internal Medicine $140,921
Dr. Jordan Vaughn, M.d, M.D
Internal Medicine — Payments: $90,874
Internal Medicine $90,874
David Deatkine, Md, MD
Internal Medicine — Payments: $83,978
Internal Medicine $83,978